Skip to main content
. 2011 Jul 26;137(9):1371–1377. doi: 10.1007/s00432-011-1007-z

Fig. 3.

Fig. 3

Patients with tumors E-Cadherin immunoreactivity rates higher than 75% named protected (magnification, ×40)